Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024
October 15, 2024 04:00 ET
|
Oculis Holding AG
ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...
Matthews International Completes Senior Notes Offering
September 30, 2024 08:00 ET
|
Matthews International Corporation
PITTSBURGH, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Matthews International Corporation (NASDAQ GSM: MATW) (“Matthews” or the “Company”) closed on September 27, 2024 on its previously announced private...
Matthews International Announces Pricing of Senior Notes
September 24, 2024 08:00 ET
|
Matthews International Corporation
PITTSBURGH, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Matthews International Corporation (NASDAQ GSM: MATW) (the “Company”) has priced its previously announced private offering of $300 million aggregate...
Matthews International Announces Proposed Private Offering of Senior Notes
September 23, 2024 08:15 ET
|
Matthews International Corporation
PITTSBURGH, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Matthews International Corporation (NASDAQ GSM: MATW) (the “Company”) today announced a proposed private offering of senior secured second lien notes...
Oculis birtir uppgjör fyrir annan ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins
August 27, 2024 04:00 ET
|
Oculis Holding AG
ZUG, Sviss, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Félagið birti jákvæðar niðurstöður fyrir fasa 2b RELIEF rannsóknina á OCS-02 (licaminlimab) sem rennir stoðum undir möguleika á fyrstu...
Oculis Reports Q2 Financial Results and Provides Recent Company Update
August 27, 2024 04:00 ET
|
Oculis Holding AG
ZUG, Switzerland, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Reported positive topline results for the Phase 2b RELIEF trial of OCS-02 (licaminlimab) paving the way for potentially the first precision...
Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update
August 27, 2024 04:00 ET
|
Oculis Holding AG
Reported positive topline results for the Phase 2b RELIEF trial of OCS-02 (licaminlimab) paving the way for potentially the first precision medicine in Dry Eye Disease (DED)Phase 2 ACUITY trial of...
Matthews International Reports Results for Fiscal 2024 Third Quarter
August 01, 2024 16:15 ET
|
Matthews International Corporation
Fiscal 2024 Third Quarter Financial Highlights: Outstanding debt reduced by $12.6 million during the quarter3rd Quarter GAAP EPS of $0.06; non-GAAP adjusted EPS of $0.56SGK Brand Solutions...
Matthews International Declares Quarterly Dividend
July 24, 2024 16:15 ET
|
Matthews International Corporation
PITTSBURGH, July 24, 2024 (GLOBE NEWSWIRE) -- Matthews International Corporation (NASDAQ GSM: MATW) announced that its Board of Directors declared, at its regularly scheduled meeting today, a...
Matthews International Announces Third Quarter Fiscal 2024 Earnings Release and Conference Call
July 12, 2024 16:15 ET
|
Matthews International Corporation
PITTSBURGH, July 12, 2024 (GLOBE NEWSWIRE) -- Matthews International Corporation (Nasdaq GSM: MATW) today announced plans to release its third quarter fiscal year 2024 earnings results after the...